We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Analysis

USPTO Memo Cuts Mayo Woes On Treatment Method Patents

Law360 (June 14, 2018, 8:36 PM EDT) -- New guidance from the U.S. Patent and Trademark Office suggests that patents on methods of treating disease should usually be considered patent-eligible, freeing patent holders from having to grapple with the convoluted eligibility analysis patents must often face, attorneys say.

The patent office put out a memo to examiners last week explaining how they should apply an April ruling by the Federal Circuit that a patent covering Vanda Pharmaceuticals Inc.'s schizophrenia drug Fanapt is eligible for patenting under the U.S. Supreme Court's Mayo test.

The office...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.